GlassScriptPhysician profile
Andleeb A Usmani
NPI 1447393251
$8,328.36
in general payments reported to CMS, 2019-2025
45 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $728 · 2021: $699 · 2022: $669 · 2023: $1,661 · 2024: $1,508 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,746.71 |
| Education | $212.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,083.80 | 2019-2025 | Dupixent |
| Abbvie INC. | $921.07 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $888.12 | 2019-2025 | |
| Pfizer INC. | $854.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $472.67 | 2019-2025 | |
| Leo Pharma INC. | $381.33 | 2019-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $330.64 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $317.11 | 2019-2025 | Blu-U, Absorica Ld, Winlevi |
| Incyte Corporation | $291.68 | 2022-2025 | Opzelura |
| Revance Therapeutics, INC. | $271.57 | 2024-2025 | Daxxify |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $261.22 | 2023 | |
| Amgen INC. | $244.43 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $240.67 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Paratek Pharmaceuticals, INC. | $184.75 | 2023-2025 | Nuzyra |
| Galderma Laboratories, L.P. | $171.51 | 2022-2025 | Nemluvio, Aklief |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andleeb Usmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.